Welcome to our dedicated page for Jaguar Health SEC filings (Ticker: JAGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Jaguar Health, Inc. (NASDAQ: JAGX) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures, giving investors structured access to its capital markets activity and material agreements. Jaguar is a commercial-stage pharmaceuticals company focused on plant-based prescription medicines for gastrointestinal distress in humans and animals, and its filings provide insight into how it finances and supports these programs.
Recent Form 8-K filings describe a range of transactions, including secured and unsecured promissory notes, royalty interest agreements and amendments, PIPE financings involving Series N Perpetual Preferred Stock and common stock with pre-funded warrants, and privately negotiated exchanges of preferred stock for common shares and pre-funded warrants. Other 8-Ks outline at-the-market offering amendments, conditional approval-related developments for Canalevia-CA1, and note purchase agreements backed by deposit account control arrangements and subsidiary guarantees.
Jaguar’s proxy materials, such as definitive proxy statements on Schedule 14A, detail stockholder proposals to approve share issuances under Nasdaq Listing Rule 5635(d), including common stock issuable upon exchange of Series L, Series M, and Series N preferred stock and upon conversion of certain convertible promissory notes and related warrants. These documents also explain voting rights, voting caps for preferred series, and the structure of special and annual meetings.
On this page, users can review Jaguar’s 10-K and 10-Q reports (when available) for broader business and risk disclosures, while Form 4 and related ownership filings provide visibility into insider equity transactions. Stock Titan enhances these filings with AI-powered summaries that highlight key terms in complex documents, such as interest rates, maturity dates, collateral arrangements, voting provisions, and share issuance conditions. Real-time updates from EDGAR ensure that new Jaguar Health filings, including 8-Ks announcing material events, are quickly accessible with plain-language explanations.
Jaguar Health, Inc. director Anula Jayasuriya received equity awards consisting of 5,870 restricted stock units and stock options covering 5,870 shares of common stock, approved by the board on December 11, 2025 under the company’s 2014 Stock Incentive Plan.
Each restricted stock unit represents a right to receive one share and vests on December 11, 2026, while the options have a $1.44 exercise price, vest monthly over 12 months from the grant date, and expire on December 11, 2035. Following these grants, she beneficially owns 5,916 shares of common stock and 5,870 stock options, held directly.
Jaguar Health, Inc. reported that its Chief Financial Officer, Carol R. Lizak, received new equity awards on December 11, 2025.
The awards include 11,740 restricted stock units, each representing a contingent right to receive one share of voting common stock for $0 consideration, with beneficial ownership of common stock reported as 11,911 shares after the transaction. She also received stock options to purchase 11,740 shares of common stock at an exercise price of $1.44 per share, expiring on December 11, 2035.
The grants were made under the company’s 2014 Stock Incentive Plan. The restricted stock units vest on December 11, 2026, and vested shares will be delivered on that vesting date, while the options vest in equal monthly installments over 12 months from the grant date, subject to continued employment.
Jaguar Health, Inc. entered into two privately negotiated exchange agreements with Iliad Research and Trading, L.P., swapping Series M Perpetual Preferred Stock for common stock and pre-funded warrants. On December 9, 2025 the company issued 400,000 common shares and a pre-funded warrant to purchase 1,304,545 common shares in exchange for 75 Series M shares, which were then cancelled and retired. On December 11, 2025 it issued 40,000 common shares and a pre-funded warrant to purchase 304,827 common shares in exchange for 16 additional Series M shares, which were also cancelled and retired. The pre-funded warrants are immediately exercisable at an exercise price of $0.001 per share and include a 9.99% beneficial ownership cap, limiting how much of Jaguar Health’s common stock Iliad and its affiliates may hold after exercise. The securities were issued under the Section 3(a)(9) exemption from Securities Act registration.
Jaguar Health, Inc. is registering up to 2,621,852 shares of common stock for resale by existing investors. These shares include 1,980,827 shares issuable upon exchange of 950.8 outstanding shares of Series N Perpetual Preferred Stock, 161,583 PIPE shares, and 479,442 shares underlying a pre-funded warrant with a $0.0001 exercise price per share. The company will not receive proceeds from stockholder resales and would receive only about $48 if the pre-funded warrant is exercised for cash.
Jaguar is a commercial-stage pharmaceutical company focused on plant-based medicines for gastrointestinal disorders in people and animals. Its lead drug crofelemer underpins approved HIV-related diarrhea treatment Mytesi, a conditionally approved veterinary product for chemotherapy-induced diarrhea in dogs, and multiple late-stage and orphan programs, including cancer therapy-related diarrhea and rare diseases such as short bowel syndrome and microvillus inclusion disease. The company is also expanding into cancer supportive care with Gelclair and exploring CNS indications through its Magdalena joint venture.
Jaguar Health, Inc. entered into new amendments to three existing royalty interest agreements, each with an original principal amount of $12 million. Beginning on April 1, 2026, the monthly royalty payment under each agreement must be the greater of $750,000 or the royalty amount otherwise owed for that month, increasing the company’s fixed payment obligation to its investors Iliad, Uptown, and Streeterville.
Jaguar and its subsidiary Napo Pharmaceuticals also amended a secured promissory note with an original principal amount of $6,220,812.50, extending its maturity date to April 1, 2026, which delays required repayment. In a separate exchange, Jaguar issued 361,271 shares of common stock in a private transaction to Streeterville in exchange for 25 shares of its Series M Preferred Stock, which were then cancelled, simplifying part of its capital structure.
Jaguar Health entered a secured financing with Streeterville Capital, issuing a $10,810,000 promissory note at 8.00% interest. The note includes an $800,000 original issue discount and $10,000 in transaction costs, both included in principal. At closing, Streeterville paid $2,000,000 to Jaguar and placed $8,000,000 into a controlled deposit account at Lakeside Bank held by a new subsidiary, JAGX Holdings, LLC.
The note matures in 36 months, is prepayable, and requires mandatory prepayments equal to 25% of Upfront Licensing Fees from any IP Transaction, capped at the then-outstanding balance. Starting on the 12‑month anniversary, the lender may redeem up to $600,000 plus accrued interest per month, payable in cash within two trading days.
Obligations are secured by the deposit account, a subsidiary guaranty, and a pledge of all JAGX Holdings membership interests. Covenants limit variable‑price and certain convertible financings, new liens, and subsidiary equity or debt without consent. Trigger Events can increase the note balance by 15% (Major) or 5% (Minor), up to three times each, with Events of Default permitting acceleration and default interest up to 18% simple interest.
Jaguar Health (JAGX) filed its Q3 2025 10‑Q, reporting total revenue of $3.083 million, essentially flat versus $3.108 million a year ago. Product sales were $3.041 million. The company posted a net loss of $9.648 million for the quarter and $30.804 million for the nine months.
Cash was $3.527 million at September 30, 2025, down from $8.002 million at year‑end. Current liabilities rose to $36.122 million (from $19.704 million), driven by notes payable current of $23.108 million. Total liabilities were $45.113 million, and stockholders’ equity was $4.359 million.
The company disclosed substantial doubt about its ability to continue as a going concern and plans to rely on additional financing and commercialization efforts. Financing inflows year‑to‑date included an ATM program ($6.331 million net), $3.445 million of convertible notes, and a PIPE for preferred shares ($2.377 million). As of November 14, 2025, there were 3,735,837 voting common shares outstanding and 9 non‑voting shares.
Jaguar Health (JAGX) called a Special Meeting for December 8, 2025 to seek stockholder approval under Nasdaq Rule 5635(d) for two financing-related items and a potential adjournment. Proposal 1 asks to approve issuing Common Stock upon exchange and/or redemption of 950.8 shares of Series N Preferred Stock. Based on a
Proposal 2 seeks approval for the September 2025 private placement: 161,583 New PIPE Shares at
Jaguar Health (JAGX) called a Special Meeting on December 8, 2025 to seek stockholder approval under Nasdaq Listing Rule 5635(d) for two financing-related issuances and a potential adjournment.
Proposal 1: Approve issuing Common Stock upon exchange and/or redemption of previously issued Series N Preferred Stock. Based on a fixed $1.20 Exchange Price and 950.8 Series N shares outstanding, up to 1,980,827 Exchange Shares (or 1,980,833 Forced Redemption Shares) could be issued. Shares outstanding were 3,734,635 as of October 17, 2025. Series N was sold for approximately $2.38 million on September 10, 2025. Series N cannot vote on Proposal 1.
Proposal 2: Approve the New PIPE Securities from September 29, 2025: 161,583 New PIPE Shares and a pre-funded warrant for up to 479,442 shares. Combined, these represent about 17.16% of Common Stock outstanding prior to exercise as of October 17, 2025. The warrant includes a 4.99% Beneficial Ownership Limitation, adjustable up to 19.99%.
Proposal 3: Allow adjournment to solicit additional proxies if needed.
FAQ
What is the current stock price of Jaguar Health (JAGX)?
What is the market cap of Jaguar Health (JAGX)?
